Citadel Advisors LLC Lowers Position in Ikena Oncology, Inc. (NASDAQ:IKNA)

Citadel Advisors LLC lessened its holdings in shares of Ikena Oncology, Inc. (NASDAQ:IKNA) by 51.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 80,368 shares of the company’s stock after selling 84,647 shares during the quarter. Citadel Advisors LLC owned about 0.17% of Ikena Oncology worth $132,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. BML Capital Management LLC increased its position in shares of Ikena Oncology by 395.8% in the fourth quarter. BML Capital Management LLC now owns 3,585,866 shares of the company’s stock worth $5,881,000 after purchasing an additional 2,862,578 shares during the last quarter. Gilead Sciences Inc. purchased a new position in Ikena Oncology in the 4th quarter worth approximately $3,294,000. Peapod Lane Capital LLC purchased a new position in Ikena Oncology in the 4th quarter worth approximately $833,000. Geode Capital Management LLC increased its holdings in shares of Ikena Oncology by 21.0% in the 4th quarter. Geode Capital Management LLC now owns 327,962 shares of the company’s stock worth $538,000 after buying an additional 56,936 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Ikena Oncology by 18,244.1% during the 4th quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company’s stock valued at $255,000 after buying an additional 154,892 shares in the last quarter. Institutional investors own 75.00% of the company’s stock.

Ikena Oncology Stock Performance

NASDAQ IKNA opened at $1.42 on Monday. Ikena Oncology, Inc. has a 52-week low of $0.97 and a 52-week high of $1.94. The company has a fifty day moving average of $1.17 and a 200-day moving average of $1.39. The company has a market capitalization of $68.53 million, a P/E ratio of -1.15 and a beta of 0.45.

Ikena Oncology (NASDAQ:IKNA) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03. As a group, analysts forecast that Ikena Oncology, Inc. will post -0.91 EPS for the current fiscal year.

Ikena Oncology Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.